Introduction {#S0001}
============

The recurrence of cervical cancer after operation is a challenging condition for several physicians, which can be resolved by reoperation or radiotherapy. The wide resection range of surgery and multiple postoperative complications are a disadvantage that cannot be accepted by many patients,[@CIT0001]--[@CIT0003] thereby rendering radiotherapy a remarkable option in the treatment of postoperative recurrent cervical cancer. However, patients cannot achieve a radical radiation dose through external beam radiation therapy because of its dosage limitation on the organs at risk (OAR),[@CIT0004] which makes brachytherapy indispensable for further treatment along with or after external beam radiation therapy. Also, brachytherapy can obviously improve the dose level of tumor tissues without a significant increase in the dose in the surrounding normal organs.[@CIT0005] The needles can be inserted into the tumor uniformly and accurately through interstitial implantation with optimal conformability, thereby achieving a high dose on the tumor for an enhanced therapeutic effect.[@CIT0006]--[@CIT0008] The 3D printed minimally invasive guidance template is a newly emerging technology that can be applied to cervical cancer with the goal of individualized treatment. Thus, the present study aimed to compare the dosimetry difference between a 3D printed minimally invasive guidance template and an unconventional implantation in the brachytherapy of postoperative recurrent cervical carcinoma.

Materials and methods {#S0002}
=====================

Clinical data {#S0002-S2001}
-------------

A total of 21 cases of postoperative recurrent cervical cancer admitted to our hospital from January 2017 to June 2018 were enrolled. The inclusion criteria were as follows: 1) pathological diagnosis of postoperative pathology which was consistent with that of recurrence after surgery; 2) imaging examination, such as pelvic magnetic resonance imaging, confirming local recurrence of different degrees; 3) no distant metastasis of other organs or tissues found in the imaging examination; and 4) no chance of reoperation or refusal to operate. All patients were randomly divided into two groups after the intensity-modulated radiotherapy dose reached 45 Gy in 25 fractions of 1.8 Gy, and were treated with a high dose of ^192^Ir 3D after loading on the brachytherapy machine, 6 Gy/fraction, 4--6 times in total. Some patients were treated with concurrent cisplatin chemotherapy (30--40 mg/m^2^, 1 time/week) during this period ([Table 1](#T0001){ref-type="table"}).[@CIT0009],[@CIT0010] There is no selection bias in the clinical characteristics of the two groups of patients. The present study was conducted under the approval, supervision, and guidance of the Ethics Committee of Cangzhou Chinese and Western Medicine Integrated Hospital, and all patients signed the informed consent to fulfill the ethical requirement. This study was conducted in accordance with the Declaration of Helsinki.Table 1Patient characteristicsVariableTemplate groupFree group*P*-valueNumber of cases (%)Number of cases111021Age (years), mean±SD53.2±7.851.8±6.90.89Pathology1.00 Squamous cell carcinoma11920 (95.2) Adenosquamous carcinoma011 (4.8)Recurrence location0.67 Simple central6612 (57.1) Central and pelvic wall549 (42.9)Tumor size (cm), mean±SD6.3±0.86.1±0.60.78Concurrent weekly cisplatin chemotherapy0.67 Yes7714 (66.7) No437 (33.3)

Procedure of 3D interstitial implantation brachytherapy {#S0002-S2002}
-------------------------------------------------------

### Design and production of the 3D printed minimally invasive guidance template {#S0002-S2002-S3001}

Patients were asked to undergo some preoperative preparation including vaginal irrigation, emptying themselves of urine and stool, radiography swallowing, and catheterization. Different types and lengths of vaginal 3D templates (QL-YXK-HZ) were selected for patients in the template group according to the length of the vagina and the narrow degree of vaginal postoperation. A volume of 120 mL saline was injected into the bladder before computed tomography (CT) scan, and images were transmitted into the Oncentra® Brachy TPS plan system. The tumor target volume and OAR were delineated by the physician based on the pelvic magnetic resonance imaging scan before the treatment, following which the images were uploaded to the planning system, Prowess Panther V4.72, through the Qilin data cloud platform (Ucloud V2.3.7). According to the design of the target area, the spatial distribution of the main needle tracks was designed, and an auxiliary stitch was also designed at 0.5 cm next to each main needle track, up/down and left/right. The data were imported into the template production system (Unicorn 3D template system V3.1) to establish a 3D model, which was then input into the 3D printer (EP-A650) ([Figure 1A](#F0001){ref-type="fig"}). Finally, an individualized 3D printed minimally invasive guidance template with a satisfactory conformability degree, including information on the needle track position, was acquired ([Figure 1B](#F0001){ref-type="fig"}).Figure 1Schematic representation of needle track design (**A**) and 3D-printed minimally invasive-guided template (**B**).

### Implantation process {#S0002-S2002-S3002}

The 3D printed minimally invasive guided template was inserted into the vagina in the template group, with the template wing fully attached to the perineum, which was further fastened by transparent dressings. The needles were inserted into the preset tracks. The position and depth of the inserted needles were adjusted according to the CT scan result. The conventional implantation in the free group was relatively simple, as described previously ([Figure 2A](#F0002){ref-type="fig"}).[@CIT0011]Figure 23D printed minimally invasive guidance template implantation (**A**) and 3D model after reconstruction of tumor target volume and organs at risk (B). Red refers to the tumor target volume, blue refers to the bladder, yellow refers to the rectum, and pink indicates the sigmoid colon.

### Treatment planning {#S0002-S2002-S3003}

The CT images were transmitted into the Oncentra Brachy TPS plan system, and the high-risk clinical target volume (HR-CTV) as well as the OAR, such as the rectum, bladder, sigmoid colon, and bowel, were delineated according to the guidelines of the European Association of Gynecological Radiotherapy.[@CIT0012],[@CIT0013] The prescription dosage of HR-CTV was 6 Gy/fraction, 1 time/week. The patients underwent brachytherapy 4--6 times ([Figure 2B](#F0002){ref-type="fig"}).

Observation variables {#S0002-S2003}
---------------------

Data for each patient were recorded with respect to the number of needles used, the number of CT scans, and the time for the implantation needle to reach a satisfactory position during every treatment. The dose distribution of the target volume was evaluated using the D~98~, D~95~, and D~90~ values of HR-CTV, and the OAR volume dose limitation was evaluated using illuminated dose of 2 cm^3^ of organ at risk (D2cm^3^).[@CIT0012],[@CIT0013]

Statistical methods {#S0002-S2004}
-------------------

The data are represented as mean±SD and analyzed using SPSS 17.0. The Wilcoxon rank sum nonparametric test was performed to compare the clinical tumor characteristics between the two groups. The two groups were tested to conform to the normal distribution, and an independent-samples *t*-test was applied. *P*\<0.05 was considered a statistically significant difference.

Results {#S0003}
=======

All patients successfully underwent 3D interstitial implantation brachytherapy 4--6 times, and 116 times in total.

Comparison of target volume and OAR: the D~98~, D~95~, and D~90~ values of HR-CTV in the template group were significantly higher than in the free implantation group (*P*\<0.05) ([Table 2](#T0002){ref-type="table"}). Compared to the free group, the D2cm^3^ value of the bladder, rectum, sigmoid colon, and bowel in the template group was significantly decreased (*P*\<0.05) ([Table 3](#T0003){ref-type="table"}). Table 2Therapeutic parameters of the target volume (mean±SD)VariableHR-CTV D~98~(Gy)HR-CTV D~95~(Gy)HR-CTV D~90~(Gy)Template group5.61±0.305.96±0.246.30±0.21Free group5.32±0.395.68±0.346.07±0.32*P*-value0.0070.0100.015[^2] Table 3Therapeutic parameters of the organs at risk (mean±SD)VariableBladder D2cm^3^ (Gy)Rectum D2cm^3^ (Gy)Sigmoid colon D2cm^3^ (Gy)Bowel D2cm^3^ (Gy)Template group4.78±0.164.05±0.213.80±0.252.91±0.22Free group5.07±0.354.32±0.314.11±0.373.23±0.39*P*-value0.0020.0120.0010.001[^3]

Number of CT scans, time of insertion, and number of needles: the average number of CT scans was 1.61±0.52 for each implantation treatment in the template group, the average consumption time for each implant treatment from the time of insertion of the needles up to that of reaching the satisfactory position was 10.21±2.16 min, and the number of needles used for each implant treatment was 5.71±1.82. Nevertheless, the data for the free implantation group were 3.12±0.82 scans, 30.52±6.08 min, and 7.78±2.35 needles, respectively, and the differences were statistically significant (*P*\<0.05) ([Table 4](#T0004){ref-type="table"}).Table 4Number of CT scans, time for insertion, and number of needles usedVariableNumber of CT scansTime for insertion (min)Number of needlesTemplate group1.61±0.5210.21±2.165.71±1.82Free group3.12±0.8230.52±6.087.78±2.35*P*-value0.0390.0010.003[^4]

Discussion {#S0004}
==========

Interventional implantation brachytherapy is usually adopted in the treatment of recurrent cervical cancer with the advantage of the degree of conformation and encompassing the target volume to the maximum, thereby achieving a satisfactory therapeutic effect.[@CIT0014]--[@CIT0016] However, this conventional technique has several limitations. First, due to an error of judgment in the insertion angle, needles can easily deviate from the direction of the original design, requiring adjustment of the direction and depth of the insertion needle several times during the treatment process, thereby prolonging the operation time and increasing the risk of complications such as local bleeding. Second, the skills and experience of surgeons play a critical role in the treatment. However, the prolonged period of this technique renders difficulty in establishing a standard. Third, multiple CT scans increase the patient's exposure to radiation. Finally, the irregular shape of the postoperative stump and vaginal stenosis may lead to poor adhesion between the applicator and mucosa, resulting in a poor distribution of the dose.[@CIT0017] For the classic transperineal template applicators, such as the Syed--Neblett butterfly applicator and the Martinez Universal Perineal Interstitial Template applicator, the distance between the template and the tumor is so large that it is difficult to ensure accuracy of the needle insertion. In addition, the risk of complications increases with the increasing number of inserted needles. Moreover, patients are required to wait with needles inserted for the whole process of treatment, which lasts for several days, causing great pain for patients.[@CIT0018],[@CIT0019] Considering the above deficiencies, our center has independently developed a 3D printed minimally invasive guidance template for the treatment of recurrent cervical cancer. Currently, no reports are available on the clinical application of this template in the treatment of recurrent cervical cancer worldwide.

The 3D printed minimally invasive guidance template adopted in this study is a technology that has newly emerged in recent years. The technology adopts 3D digitization to establish an individualized template, which contains the needle track information of the designed plan and can be used for preplanning the design in order to guarantee the conformability and accuracy of the tumor target volume. The angle and depth of insertion can be rapidly achieved with the help of predesigned needle tracks, thereby reducing the difficulty of operation and shortening the operation time. In addition, the technology not only limits residual irradiation but also significantly reduces the OAR dose and substantially reduces treatment pain.[@CIT0020],[@CIT0021] Several studies have investigated the application of a 3D printing template for particle implantation therapy,[@CIT0022]--[@CIT0024] suggesting the advantages of accurate localization and orientation, and deeming it an effective and accurate auxiliary tool.

The radiation dose D~90~ value of the HR-CTV should be between 80 and 90 Gy as recommended by the American Brachytherapy Society.[@CIT0025] In this study, all of the doses for the target volume fulfilled the requirement; however, a significantly high dose could be achieved for the target volume in the template group as compared to the free group.[@CIT0026] Also, it is recommended that the bladder D2cm^3^ value is \<90 Gy EQD2, and the D2cm^3^ value of the rectum and sigmoid colon is \<75 Gy EQD2. In this study, the cumulative doses of the OAR for all patients met the requirement, with the dose of the OAR in the template group significantly lower than that of the free group. Liu et al[@CIT0011] studied 16 cases of recurrent cervical carcinoma treated by free needle implantation guided by CT and found that the average number of CT scans was 3.1±0.9, the average time from the first implantation to the final CT scan was 30.9±8.6 min, and the average number of needles was 6.1±1.5, which are similar results to those of the free group in the current study. Conversely, fewer CT scans were required for the template group, the adjustment time was shorter, and the number of therapeutic needles was lower. These factors lessened the pain. Therefore, studies with a larger sample size are an urgent requisite to verify the conclusion achieved by those involving a smaller number of samples.

Conclusion {#S0005}
==========

The 3D minimally invasive guidance template has wide application in the brachytherapy of postoperative recurrent cervical cancer with accurate localization, improved repeatability, short operation time, and a lower number of needles. However, further observation is essential to deduce the long-term efficacy and side effects of the technology.
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